Literature DB >> 12687385

Comparison of once- versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis.

R Giger1, P Pasche, C Cheseaux, L Cantini, A Rossetti, B N Landis, J S Lacroix.   

Abstract

The aim of the study was to assess the efficacy and safety of nasal aqueous beclomethasone dipropionate (BDP), 400 micro g/day, given via a metered pump in a once-daily or twice-daily regimen following a double-blind, parallel group design over a 12-week period. Adult patients (n=112) with allergic or non-allergic chronic rhinosinusitis recorded their nasal and ocular symptoms for the 7-day run-in period and for the first 4 weeks of treatment. At baseline and after 4 weeks the airways' resistance via active anterior rhinomanometry and the volume and area section via acoustic rhinometry were measured. Morning serum cortisol was measured at baseline and at week 12. Adverse events were to be reported at each visit. Of the 112 randomised patients, three did not enter the ITT analysis and another 13 in total discontinued the treatment. Significant improvements over the baseline were reported in both groups for the primary variable sum of nasal scores (-53.7% in the once-daily group and -59.7 in the twice-daily group), as well as for each nasal and ocular symptoms, without differences between the groups. Because of a wider variability than expected, the 95% confidence interval (C.I.) for the difference between the least square means exceeded the pre-defined limit of +/-10% of the reference mean. Similar improvements in both groups were also reported for the nasal airway patency's parameters. The total number of drug-related adverse events was 26 in the once-daily group and 32 in the twice-daily group, with most of the events consisting of local effects at the site of application. No signs of adrenal suppression were observed, and serum morning cortisol values did not significantly change. The once-daily BDP dosing (400 micro g/day) therefore has a similar efficacy and safety profile as the same daily dose given in a twice-daily regimen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12687385     DOI: 10.1007/s00405-002-0543-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  11 in total

Review 1.  Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis.

Authors:  Kornkiat Snidvongs; Larry Kalish; Raymond Sacks; Rahuram Sivasubramaniam; Daron Cope; Richard J Harvey
Journal:  Am J Rhinol Allergy       Date:  2013 May-Jun       Impact factor: 2.467

Review 2.  Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool.

Authors:  Ratika Gupta; Luz S Fonacier
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

3.  Chronic rhinosinusitis in children.

Authors:  Hassan H Ramadan
Journal:  Int J Pediatr       Date:  2011-10-05

4.  Drug management in chronic rhinosinusitis: identification of the needs.

Authors:  Jean-Baptiste Hpj Watelet; Philippe H Eloy; Paul B van Cauwenberge
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

5.  Cost-effectiveness analysis of mometasone furoate versus beclomethasone dipropionate for the treatment of pediatric allergic rhinitis in Colombia.

Authors:  Carlos E Rodríguez-Martínez; Monica P Sossa-Briceño; Elkin Vladimir Lemos
Journal:  Adv Ther       Date:  2015-03-10       Impact factor: 3.845

6.  Magnetic nanoparticles: a new tool for antibiotic delivery to sinonasal tissues. Results of preliminary studies.

Authors:  K Dobretsov; S Stolyar; A Lopatin
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-04       Impact factor: 2.124

Review 7.  Different types of intranasal steroids for chronic rhinosinusitis.

Authors:  Lee Yee Chong; Karen Head; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26

8.  The treatment of vasomotor rhinitis with intranasal corticosteroids.

Authors:  Eli O Meltzer
Journal:  World Allergy Organ J       Date:  2009-08-15       Impact factor: 4.084

9.  Chronic rhinosinusitis and emerging treatment options.

Authors:  Patorn Piromchai; Pornthep Kasemsiri; Supawan Laohasiriwong; Sanguansak Thanaviratananich
Journal:  Int J Gen Med       Date:  2013-06-07

Review 10.  Safety of intranasal corticosteroids in acute rhinosinusitis.

Authors:  Pascal Demoly
Journal:  Am J Otolaryngol       Date:  2008-06-16       Impact factor: 1.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.